Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 3/20 | 0.42 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.42 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.42 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.42 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
| ▸ | ADK | P55263 | 1/20 | 0.41 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | BTK | Q06187 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.36 |
| ▸ | KDR | P35968 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrazinecarboxamide SCHEMBL4712502 | 0.89 | CSNK1A1 (0.46) | ADRA2ACSNK1A1TYRO3DYRK1BMTOR | |
| SCHEMBL30979447 | 0.78 | ADRA2A (0.46) | ADRA2ACSNK1A1TYRO3DYRK1BMTOR | |
| SCHEMBL6824177 | 0.75 | MTOR (0.54) | ADRA2ACSNK1A1TYRO3DYRK1BMTOR | |
| SCHEMBL28678460 | 0.74 | ALDH1A1 (0.47) | ALDH1A1GAANPC1RAB9AMAPT | |
| SCHEMBL39553 | 0.73 | ALDH1A1 (0.47) | ADRA2ACSNK1A1TYRO3DYRK1BMTOR | |
| SCHEMBL4329170 | 0.73 | ADRA2A (0.50) | ADRA2ACSNK1A1TYRO3DYRK1BMTOR | |
| SCHEMBL21298118 | 0.71 | ADRA2A (0.49) | ADRA2ACSNK1A1TYRO3DYRK1BMTOR | |
| SCHEMBL38662055 | 0.71 | CSNK1A1 (0.53) | ADRA2ACSNK1A1TYRO3DYRK1BMTOR | |
| SCHEMBL1663671 | 0.71 | CSNK1A1 (0.53) | ADRA2ACSNK1A1TYRO3DYRK1BMTOR | |
| SCHEMBL7660143 | 0.70 | NPC1 (0.44) | ADRA2AMTORADKNISCHIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250041408-A1 | SMALL MOLECULE IMMUNOPOTENTIATOR CONJUGATES OF NFKB ACTIVATORS AS ADJUVANTS WITH ENHANCED EFFICACY AND REDUCED TOXICITY | THE UNIVERSITY OF CHICAGO | 2025-02-06 | — | — | US | disclosed |
| EP-4493275-A1 | METHODS AND COMPOSITIONS FOR IMPROVING IN VIVO SURVIVAL OF MIDBRAIN DOPAMINE NEURONS | Memorial Sloan Kettering Cancer Center (US) | 2025-01-22 | — | — | EP | disclosed |
| US-20250017979-A1 | METHODS AND COMPOSITIONS FOR IMPROVING IN VIVO SURVIVAL OF MIDBRAIN DOPAMINE NEURONS | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2025-01-16 | — | — | US | disclosed |
| WO-2023177919-A1 | METHODS AND COMPOSITIONS FOR IMPROVING IN VIVO SURVIVAL OF MIDBRAIN DOPAMINE NEURONS | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2023-09-21 | — | — | WO | disclosed |
| US-20220387561-A1 | TREATMENT OF SEVERE ACUTE RESPIRATORY SYNDROME-RELATED CORONAVIRUS INFECTION WITH KLOTHO | COSTA RICAN SOCIAL SECURITY FUND / CAJA COSTARRICENSE DE SEGURO SOCIAL CCSS (CR) | 2022-12-08 | — | — | US | disclosed |
| US-20220008519-A1 | TREATMENT OF SEVERE ACUTE RESPIRATORY SYNDROME-RELATED CORONAVIRUS INFECTION WITH KLOTHO | Costa Rican Social Security Fund / Caja Costarricense de Seguro Social (CCSS) (CR) | 2022-01-13 | — | — | US | disclosed |
| WO-2022008971-A2 | TREATMENT OF SEVERE ACUTE RESPIRATORY SYNDROME-RELATED CORONAVIRUS INFECTION WITH KLOTHO | Costa Rican Social Security Fund / Caja Costarricense de Seguro Social (CCSS) (CR) | 2022-01-13 | — | — | WO | disclosed |
| US-20210346495-A1 | METHODS AND COMPOSITIONS COMPRISING AN NFKB INHIBITOR AND AN ADJUVANT | THE UNIVERSITY OF CHICAGO (US) | 2021-11-11 | — | — | US | disclosed |
| EP-2827890-B1 | IMMUNOMODULATORY AGENT AND USES THEREFOR | UNIV QUEENSLAND (AU) | 2019-08-28 | — | — | EP | disclosed |
| EP-2077821-B1 | COMPOSITIONS AND METHODS FOR MODULATING IMMUNE RESPONSES | UNIV QUEENSLAND (AU) | 2019-08-14 | — | — | EP | disclosed |
| US-9453226-B2 | Protection of cells from Alu-RNA-induced degeneration and inhibitors for protecting cells | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2016-09-27 | — | — | US | disclosed |
| US-20110268722-A1 | COMBINATION THERAPIES WITH MITOCHONDRIAL-TARGETED ANTI-TUMOR AGENTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-11-03 | — | — | US | disclosed |
| WO-2011133879-A2 | COMBINATION THERAPIES WITH MITOCHONDRIAL-TARGETED ANTI-TUMOR AGENTS | UNIVERSITY OF MASSACHUSETTS (US) | 2011-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110268722-A1 | COMBINATION THERAPIES WITH MITOCHONDRIAL-TARGETED ANTI-TUMOR AGENTS | TFAM, AIFM1, MAVS | ADRA2A 2756/4885CSNK1A1 3568/4885TYRO3 1968/4885 |
| US-20210346495-A1 | METHODS AND COMPOSITIONS COMPRISING AN NFKB INHIBITOR AND AN ADJUVANT | NFKBIA, IKBKG, NFKB2 | ADRA2A 3659/4885CSNK1A1 209/4885TYRO3 552/4885 |
| US-20250041408-A1 | SMALL MOLECULE IMMUNOPOTENTIATOR CONJUGATES OF NFKB ACTIVATORS AS ADJUVANTS WITH ENHANCED EFFICACY AND REDUCED TOXICITY | NFKBIA, NFRKB, NFKB2 | ADRA2A 2200/4885CSNK1A1 1933/4885TYRO3 216/4885 |
| US-20250017979-A1 | METHODS AND COMPOSITIONS FOR IMPROVING IN VIVO SURVIVAL OF MIDBRAIN DOPAMINE NEURONS | CHAT, PINK1, DBH | ADRA2A 2600/4885CSNK1A1 1148/4885TYRO3 3960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.